Prognostic value of plasma HIV RNA and CD4+ count for clinical endpoints in CPCRA 036 melanie

A. Thompson, G. Perez, J. Neaton, S. Howard, J. Baxter, M. Dehlinger, D. Mayers, Rodger David MacArthur, D. Chernoff

Research output: Contribution to journalArticle

Abstract

Objective: To compare the prognostic value of HIV RNA and CD4+ cell count for disease progression and survival. Methods: Patients with CD4+ < 300 cells/μl were enrolled in a strategy trial of decision making with or without plasma HIV RNA quantitation. Two HIV RNA (hDNA) and CD4+ assays were obtained at baseline for all patients and at least every four months in 66% of patients. Proportional hazards regression was used to assess the relationship of HIV RNA and CD4+ to clinical disease progression and death over a median follow-up of 12 months. Results: 1485 patients were enrolled of whom 219 had clinical events. At baseline, median HIV RNA and CD4+ counts were 40.4 Keq/ml and 155 cells/μl. A 0.5 log lower viral load at baseline was associated with a 30% lower rate of disease progression (p<0.0001) after adjustment for baseline CD4+. Relative risk (RR) estimates for each of the upper tertiles of baseline HIV RNA compared to the lower tertile were 1.5 (p=0.13) and 3.3 (p=0.0001) after adjustment for log CD4+. For baseline CD4+ cell count, RRs for each of the lower two tertiles compared to the highest were 3.3 (p=0.0004) and 10.9 (p=0.0001) after adjustment for log HIV RNA. A 0.5 log decrease in HIV RNA at 4 months was associated with a 35% lower risk of disease progression (p<0.0001), adjusted for CD4+ change. Conclusions: Baseline CD4+ was a stronger predictor of disease progression or death than baseline HIV RNA in this population. Both baseline and change in HIV RNA after 4 months were strong predictors of progression.

Original languageEnglish (US)
Number of pages1
JournalClinical Infectious Diseases
Volume25
Issue number2
StatePublished - Dec 1 1997

Fingerprint

CD4 Lymphocyte Count
HIV
RNA
Disease Progression
Viral Load
Decision Making
Survival

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Cite this

Thompson, A., Perez, G., Neaton, J., Howard, S., Baxter, J., Dehlinger, M., ... Chernoff, D. (1997). Prognostic value of plasma HIV RNA and CD4+ count for clinical endpoints in CPCRA 036 melanie. Clinical Infectious Diseases, 25(2).

Prognostic value of plasma HIV RNA and CD4+ count for clinical endpoints in CPCRA 036 melanie. / Thompson, A.; Perez, G.; Neaton, J.; Howard, S.; Baxter, J.; Dehlinger, M.; Mayers, D.; MacArthur, Rodger David; Chernoff, D.

In: Clinical Infectious Diseases, Vol. 25, No. 2, 01.12.1997.

Research output: Contribution to journalArticle

Thompson, A, Perez, G, Neaton, J, Howard, S, Baxter, J, Dehlinger, M, Mayers, D, MacArthur, RD & Chernoff, D 1997, 'Prognostic value of plasma HIV RNA and CD4+ count for clinical endpoints in CPCRA 036 melanie', Clinical Infectious Diseases, vol. 25, no. 2.
Thompson A, Perez G, Neaton J, Howard S, Baxter J, Dehlinger M et al. Prognostic value of plasma HIV RNA and CD4+ count for clinical endpoints in CPCRA 036 melanie. Clinical Infectious Diseases. 1997 Dec 1;25(2).
Thompson, A. ; Perez, G. ; Neaton, J. ; Howard, S. ; Baxter, J. ; Dehlinger, M. ; Mayers, D. ; MacArthur, Rodger David ; Chernoff, D. / Prognostic value of plasma HIV RNA and CD4+ count for clinical endpoints in CPCRA 036 melanie. In: Clinical Infectious Diseases. 1997 ; Vol. 25, No. 2.
@article{1a888497ac4847469d85923cb68feed6,
title = "Prognostic value of plasma HIV RNA and CD4+ count for clinical endpoints in CPCRA 036 melanie",
abstract = "Objective: To compare the prognostic value of HIV RNA and CD4+ cell count for disease progression and survival. Methods: Patients with CD4+ < 300 cells/μl were enrolled in a strategy trial of decision making with or without plasma HIV RNA quantitation. Two HIV RNA (hDNA) and CD4+ assays were obtained at baseline for all patients and at least every four months in 66{\%} of patients. Proportional hazards regression was used to assess the relationship of HIV RNA and CD4+ to clinical disease progression and death over a median follow-up of 12 months. Results: 1485 patients were enrolled of whom 219 had clinical events. At baseline, median HIV RNA and CD4+ counts were 40.4 Keq/ml and 155 cells/μl. A 0.5 log lower viral load at baseline was associated with a 30{\%} lower rate of disease progression (p<0.0001) after adjustment for baseline CD4+. Relative risk (RR) estimates for each of the upper tertiles of baseline HIV RNA compared to the lower tertile were 1.5 (p=0.13) and 3.3 (p=0.0001) after adjustment for log CD4+. For baseline CD4+ cell count, RRs for each of the lower two tertiles compared to the highest were 3.3 (p=0.0004) and 10.9 (p=0.0001) after adjustment for log HIV RNA. A 0.5 log decrease in HIV RNA at 4 months was associated with a 35{\%} lower risk of disease progression (p<0.0001), adjusted for CD4+ change. Conclusions: Baseline CD4+ was a stronger predictor of disease progression or death than baseline HIV RNA in this population. Both baseline and change in HIV RNA after 4 months were strong predictors of progression.",
author = "A. Thompson and G. Perez and J. Neaton and S. Howard and J. Baxter and M. Dehlinger and D. Mayers and MacArthur, {Rodger David} and D. Chernoff",
year = "1997",
month = "12",
day = "1",
language = "English (US)",
volume = "25",
journal = "Clinical Infectious Diseases",
issn = "1058-4838",
publisher = "Oxford University Press",
number = "2",

}

TY - JOUR

T1 - Prognostic value of plasma HIV RNA and CD4+ count for clinical endpoints in CPCRA 036 melanie

AU - Thompson, A.

AU - Perez, G.

AU - Neaton, J.

AU - Howard, S.

AU - Baxter, J.

AU - Dehlinger, M.

AU - Mayers, D.

AU - MacArthur, Rodger David

AU - Chernoff, D.

PY - 1997/12/1

Y1 - 1997/12/1

N2 - Objective: To compare the prognostic value of HIV RNA and CD4+ cell count for disease progression and survival. Methods: Patients with CD4+ < 300 cells/μl were enrolled in a strategy trial of decision making with or without plasma HIV RNA quantitation. Two HIV RNA (hDNA) and CD4+ assays were obtained at baseline for all patients and at least every four months in 66% of patients. Proportional hazards regression was used to assess the relationship of HIV RNA and CD4+ to clinical disease progression and death over a median follow-up of 12 months. Results: 1485 patients were enrolled of whom 219 had clinical events. At baseline, median HIV RNA and CD4+ counts were 40.4 Keq/ml and 155 cells/μl. A 0.5 log lower viral load at baseline was associated with a 30% lower rate of disease progression (p<0.0001) after adjustment for baseline CD4+. Relative risk (RR) estimates for each of the upper tertiles of baseline HIV RNA compared to the lower tertile were 1.5 (p=0.13) and 3.3 (p=0.0001) after adjustment for log CD4+. For baseline CD4+ cell count, RRs for each of the lower two tertiles compared to the highest were 3.3 (p=0.0004) and 10.9 (p=0.0001) after adjustment for log HIV RNA. A 0.5 log decrease in HIV RNA at 4 months was associated with a 35% lower risk of disease progression (p<0.0001), adjusted for CD4+ change. Conclusions: Baseline CD4+ was a stronger predictor of disease progression or death than baseline HIV RNA in this population. Both baseline and change in HIV RNA after 4 months were strong predictors of progression.

AB - Objective: To compare the prognostic value of HIV RNA and CD4+ cell count for disease progression and survival. Methods: Patients with CD4+ < 300 cells/μl were enrolled in a strategy trial of decision making with or without plasma HIV RNA quantitation. Two HIV RNA (hDNA) and CD4+ assays were obtained at baseline for all patients and at least every four months in 66% of patients. Proportional hazards regression was used to assess the relationship of HIV RNA and CD4+ to clinical disease progression and death over a median follow-up of 12 months. Results: 1485 patients were enrolled of whom 219 had clinical events. At baseline, median HIV RNA and CD4+ counts were 40.4 Keq/ml and 155 cells/μl. A 0.5 log lower viral load at baseline was associated with a 30% lower rate of disease progression (p<0.0001) after adjustment for baseline CD4+. Relative risk (RR) estimates for each of the upper tertiles of baseline HIV RNA compared to the lower tertile were 1.5 (p=0.13) and 3.3 (p=0.0001) after adjustment for log CD4+. For baseline CD4+ cell count, RRs for each of the lower two tertiles compared to the highest were 3.3 (p=0.0004) and 10.9 (p=0.0001) after adjustment for log HIV RNA. A 0.5 log decrease in HIV RNA at 4 months was associated with a 35% lower risk of disease progression (p<0.0001), adjusted for CD4+ change. Conclusions: Baseline CD4+ was a stronger predictor of disease progression or death than baseline HIV RNA in this population. Both baseline and change in HIV RNA after 4 months were strong predictors of progression.

UR - http://www.scopus.com/inward/record.url?scp=33748207311&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748207311&partnerID=8YFLogxK

M3 - Article

VL - 25

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

SN - 1058-4838

IS - 2

ER -